Acrongenomics signs $6.5 million technology agreement with Molecular Vision

By Elaine Rigoli

Tampa, Fla., May 22 - Acrongenomics, Inc. and Molecular Vision, Ltd. have formed a joint collaboration intended to accelerate the development and commercialization of low-cost point-of-care (POC) diagnostic devices for personalized medical testing.

The project outlined in the collaboration is intended to support the development of novel POC devices for on-the-spot diagnosis of diabetes management, sexually transmitted diseases, cardiovascular diseases and substance abuse, based on the BioLED technology developed by the Molecular Vision.

"With diagnostics and therapeutics converging in today's health care market, Acrongenomics and Molecular Vision embark on a promising partnership to tackle the tough technical challenges associated with personalized medicine," Acrongenomics president Constantine D. Poulios said in a news release.

"Through the combined strength of our teams, we will be able to deliver revolutionary POC diagnostics to market and provide sophisticated tools demanded by the global medical community."

Molecular Vision, based in London, is an Imperial Innovations spin-off company.

With headquarters in Geneva, Switzerland, Acrongenomics is focused on investing and commercializing novel technology platforms concerning the life sciences sector.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.